PAUL R. KIRCHGRABER
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About PAUL R. KIRCHGRABER
PAUL R. KIRCHGRABER is recorded as CEO at Labcorp Holdings Inc. (LH). The proxy statement of Labcorp Holdings Inc. reports total compensation of $3,016,933 for PAUL R. KIRCHGRABER in fiscal 2022, including a base salary of $630,000. Disclosed compensation is on record for 3 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Labcorp Holdings Inc.
Other people whose current roles at this company are on record from its filings.
- DAVID P. KING CEO
- JOHN D. RATLIFF CEO
- Thomas (Tom) Pike CEO, Chairman
- Julia Wang CFO
- MARK S. SCHROEDER COO
- Adam Schechter Board Member
- Garheng Kong Board Member
- JEFFREY A. DAVIS Board Member
- John H. Sampson, M.D., Ph.D. Board Member
- KATHRYN E. WENGEL Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Labcorp Holdings Inc. (LH) | Executive Vice President and Chief Executive Officer, Early Development, Central Laboratories and Oncology | $630,000 | $3,016,933 |
| 2021 | Labcorp Holdings Inc. (LH) | Executive Vice President, Chief Executive Officer, Drug Development | $625,838 | $4,421,426 |
| 2020 | Labcorp Holdings Inc. (LH) | Executive Vice President, Chief Executive Officer, Drug Development | $606,000 | $2,973,651 |
Recent activity
No call appearances or filed executive changes recorded yet.